ES546564A0 - Procedimiento para preparar anticuerpos monoclonales y deri-vados de los mismos - Google Patents

Procedimiento para preparar anticuerpos monoclonales y deri-vados de los mismos

Info

Publication number
ES546564A0
ES546564A0 ES546564A ES546564A ES546564A0 ES 546564 A0 ES546564 A0 ES 546564A0 ES 546564 A ES546564 A ES 546564A ES 546564 A ES546564 A ES 546564A ES 546564 A0 ES546564 A0 ES 546564A0
Authority
ES
Spain
Prior art keywords
derivatives
procedure
monoclonal antibodies
preparing monoclonal
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES546564A
Other languages
English (en)
Other versions
ES8703895A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB848421944A external-priority patent/GB8421944D0/en
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES546564A0 publication Critical patent/ES546564A0/es
Publication of ES8703895A1 publication Critical patent/ES8703895A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ES546564A 1984-08-30 1985-08-30 Procedimiento para preparar anticuerpos monoclonales y deri-vados de los mismos Expired ES8703895A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB848421944A GB8421944D0 (en) 1984-08-30 1984-08-30 Monoclonal antibodies
GB858515538A GB8515538D0 (en) 1984-08-30 1985-06-19 Monoclonal antibodies

Publications (2)

Publication Number Publication Date
ES546564A0 true ES546564A0 (es) 1987-03-01
ES8703895A1 ES8703895A1 (es) 1987-03-01

Family

ID=26288164

Family Applications (2)

Application Number Title Priority Date Filing Date
ES546564A Expired ES8703895A1 (es) 1984-08-30 1985-08-30 Procedimiento para preparar anticuerpos monoclonales y deri-vados de los mismos
ES555613A Expired ES8800845A1 (es) 1984-08-30 1986-06-02 Procedimiento para preparar anticuerpos monoclonales y derivados de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES555613A Expired ES8800845A1 (es) 1984-08-30 1986-06-02 Procedimiento para preparar anticuerpos monoclonales y derivados de los mismos

Country Status (11)

Country Link
EP (1) EP0173648A3 (es)
AU (1) AU4688785A (es)
DK (1) DK391785A (es)
ES (2) ES8703895A1 (es)
FI (1) FI853283L (es)
GR (1) GR852099B (es)
HU (1) HUT38391A (es)
IL (1) IL76247A0 (es)
NO (1) NO853397L (es)
NZ (1) NZ213293A (es)
PT (1) PT81040B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202252A (en) * 1982-03-05 1993-04-13 Houston Biotechnology Inc. Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction
US5616122A (en) * 1986-11-04 1997-04-01 Baylor College Of Medicine Methods and compositions for preventing secondary cataracts
US5055291A (en) * 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
CA1338777C (en) * 1986-11-04 1996-12-10 Dominic Man-Kit Lam Methods and compositions for preventing secondary cataracts
US5104652A (en) * 1986-11-13 1992-04-14 Sloan-Kettering Institute For Cancer Research Compositions and method for treatment of cancer using monoclonal antibody against GD3 ganglioside together with IL-2
US5237054A (en) * 1987-02-20 1993-08-17 Akzo Pharma Stabilized aqueous composition containing antibodies
DE3877015T2 (de) * 1987-02-20 1993-05-06 Akzo Nv Antikoerper enthaltende stabilisierte waesserige zusammensetzung.
US5073493A (en) * 1987-05-29 1991-12-17 Ikuo Yamashina Monoclonal antibody nky13
WO1989002599A1 (en) * 1987-09-08 1989-03-23 The Biomembrane Institute Detection of survived, undegraded carbohydrate epitopes as diagnostic of intestinal diseases
US5030723A (en) * 1988-05-31 1991-07-09 The Biomembrane Institute Long-chain glycolipid structure
US5242824A (en) * 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
AU781171B2 (en) * 1997-06-10 2005-05-12 Lpath Therapeutics, Inc. Methods for early detection of heart disease
CA2432978C (en) * 2000-12-22 2012-08-28 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US8796429B2 (en) 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9217749B2 (en) 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
AU2007313822A1 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
CN101679506B (zh) 2006-10-27 2015-02-25 勒帕斯公司 用于结合鞘氨醇-1-磷酸的组合物和方法
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906562A (en) * 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas
EP0209493A3 (en) * 1985-07-16 1988-05-04 Ciba-Geigy Ag Prophylaxis and treatment of whooping cough

Also Published As

Publication number Publication date
NZ213293A (en) 1988-11-29
FI853283L (fi) 1986-03-01
PT81040B (en) 1987-06-24
DK391785A (da) 1986-03-01
EP0173648A3 (en) 1988-04-27
HUT38391A (en) 1986-05-28
PT81040A (en) 1985-09-01
ES8800845A1 (es) 1987-12-01
EP0173648A2 (en) 1986-03-05
IL76247A0 (en) 1986-01-31
GR852099B (es) 1986-01-02
FI853283A0 (fi) 1985-08-28
DK391785D0 (da) 1985-08-29
AU4688785A (en) 1986-03-06
NO853397L (no) 1986-03-03
ES555613A0 (es) 1987-12-01
ES8703895A1 (es) 1987-03-01

Similar Documents

Publication Publication Date Title
ES555613A0 (es) Procedimiento para preparar anticuerpos monoclonales y derivados de los mismos
MX159807A (es) Procedimiento para preparar derivados de bencimidazol
ES535978A0 (es) Procedimiento para preparar derivados de tiazol
ES532765A0 (es) Procedimiento para preparar derivados de 3-bencilidenalcanfor
ES526381A0 (es) Procedimiento para preparar derivados de fenil-1-piperidino-2-propanol
ES544204A0 (es) Procedimiento para preparar dialcoxipiridinas
ES542976A0 (es) Procedimiento para preparar pirrolo-bencimidazoles
ES543186A0 (es) Procedimiento para preparar nuevos derivados de aminotetra- lina
ES548323A0 (es) Procedimiento para preparar derivados de benzodifuranona
ES540464A0 (es) Procedimiento para preparar derivados de pleuromutilina
ES536666A0 (es) Procedimiento para la obtencion de colorantes reactivos de trifendioxacina
ES536138A0 (es) Procedimiento para preparar derivados azolicos
ES550730A0 (es) Procedimiento para preparar poliesterpolioles
ES539255A0 (es) Procedimiento para preparar derivados de isoquinoleina
MX159654A (es) Procedimiento para preparar derivados de hidroxi-4-2h-1-benzotiopiran-2-onas
MX157033A (es) Procedimiento para preparar derivados de pirrolo quinoleina
ES549975A0 (es) Procedimiento para preparar n-formil-&-aspartil fenilalanina
ES539717A0 (es) Procedimiento para preparar derivados azolilalquilicos
MX7403E (es) Procedimiento para preparar derivados de benzoil-ureas
ES534377A0 (es) Procedimiento para preparar derivados de antraciclina
ES548237A0 (es) Procedimiento para preparar n6-bicicloadenosinas
ES543985A0 (es) Procedimiento para preparar derivados de butiramida
ES544622A0 (es) Procedimiento para preparar l-fenilalamina
MX11506A (es) Procedimiento para la preparacion de colorantes diazoicos hidrosolubles
ES530626A0 (es) Procedimiento para preparar derivados de ciano-2-imidazopiridina